- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04891744
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Phase Ib/II Study of ATG-010 in Combination With Thalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a single-arm and open-label phase Ib/IIa study of Relapsed/Refractory Multiple Myeloma patients who have received at least one prior lines of treatment therapy; Approximately 3-48 patients will be enrolled in the study. In dose escalation phase, patients with RRMM will be treated with thalidomide 100mg/d, dexamethasone 20mg biweekly, and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively.
Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.
This arm is 4 weeks per cycle and include a total of 12 cycles.Selinexor RP2D,Thalidomide will be given at 100mg/d d1-28, and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. If a patient develops partial intolerance to glucocorticoids (as determined by the Investigator) during the study, a dose reduction of dexamethasone maximum to 10 mg is permitted. If patients do not tolerate this dose, a potential discontinuation or further dose reduction would be allowed.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Li Zheng, M.D., Ph.D
- Telefonnummer: +86-028-85423655
- E-post: lzheng2005618@163.com
Studiesteder
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital of Sichuan University
-
Ta kontakt med:
- Li Zheng, MD.PhD
- Telefonnummer: +86-028-85423655
- E-post: lzheng2005618@163.com
-
Hovedetterforsker:
- Ting Niu, M.D.,Ph.d
-
Hovedetterforsker:
- Li Zheng, M.D.,Ph.d
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
- Known and written informed consent (ICF) voluntarily.
- Age ≥ 18 years and ≤ 75 years.
- Patients with multiple myeloma who have received first-line treatment (induction, autologous transplantation and maintenance as the same first-line treatment) and achieved at least partial remission in induction.
- At or after accepting first-line regimen, subjects must have progression disease (PD) recorded which is determined by researcher according to IMWG criteria.
- Any clinically significant non-hematological toxicities (except for hair loss, peripheral neuropathy, which is otherwise stipulated in Article 13 of the exclusion criteria) that relevant to previous therapies must have resolved to ≤Grade 2 prior to first dose of study drug.
- Adequate hepatic function: total bilirubin < 2× upper limit of normal (ULN) (for patients with Gilbert's syndrome, a total bilirubin of < 3× ULN is required), AST < 2.5× ULN, and ALT < 2.5× ULN.
- Adequate renal function: estimated creatinine clearance ≥ 20 mL/min (calculated using the formula of Cockroft-Gault).
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
Measurable MM as defined by at least one of the following:
- Serum M-protein (SPEP) ≥ 10 g/L
- 24 hours-Urinary M-protein excretion ≥ 0.2 g (200 mg)
- Serum FLC ≥ 100 mg/L with abnormal FLC ratio
- Expected survival is more than 6 months.
Adequate hematopoietic function (no blood transfusion within 2 weeks and no G-CSF/GM-CSF supportive treatment within 1 week prior to screening test):
- Hemoglobin level ≥ 80 g/L
- ANC ≥ 1,000/mm3 (1.0×109/L)
- Platelet count ≥ 75,000/mm3 (75×109/L)
Female patients of childbearing potential must meet below two criteria:
- must agree to use effective contraception methods since signature in ICF, throughout the study and for 3 months following the last dose of study treatment.
- must have a negative serum pregnancy test at screening. Note: A woman is considered of childbearing potential following menarche and until becoming postmenopausal (defined as no menstrual period for a minimum of 12 months) or permanently sterile (having undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy). A woman who is taking oral contraceptive or using intrauterine device is considered of childbearing potential.
- Male patients (including those who have received vasectomy) must use a condom if sexually active with a female of child-bearing potential throughout the study and for 3 months following the last dose of study treatment.
Exclusion Criteria:
Patients who meet any of the following criteria will not be enrolled:
- Asymptomatic (smoldering) MM.
- Plasma cell leukemia.
- Documented active amyloidosis.
- Previously refractory or intolerant to immunomodulators.
- Pregnancy or breastfeeding.
- Major surgery was performed within 4 weeks prior to the first study.
Patients with active, unstable cardiovascular diseases, fits any of the following:
- Symptomatic ischemia, or
- Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with first-degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) are allowed), or
- Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3, or
- Acute myocardial infarction (AMI) within 3 months prior to the first dose of study drug.
- Uncontrolled active infection within 1 week prior to the first dose of study drug.
- Known HIV positive.
Known active hepatitis A, B, or C infection; or known positive for HCV RNA or HBsAg.
(Note: patients with HBsAg negative but HBc Ab positive need further HBV-DNA test, excluded if HBV-DNA ≥103 , if HBV-DNA <103 need anti-viral drugs)
- Prior malignancy that required treatment or has shown evidence of recurrence (except for skin basal-cell carcinoma and in-situ carcinoma including squamous cell carcinoma, bladder cancer in situ, endometrial cancer in situ, cervical cancer in situ/atypical hyperplasia, prostate cancer incidental finding (T1a or T1b), or breast cancer in situ) within 5 years prior to the first dose of study drug.
- Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
- Grade ≥ 3 peripheral neuropathy, and Grade ≥ 2 painful neuropathy, within 3 weeks prior to the first dose of study drug.
- Previous history of deep vein thrombosis.
- Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.
- Participation in an investigational anti-cancer clinical study within 3 weeks or 5 half-lives (T1/2) prior to the first dose of study drug.
- Received ASCT within 12 weeks prior to the first dose of study drug or previous allogeneic stem cell transplantation (no time limitation).
- Treatment with an approved or trial anticancer drug was given within 4 weeks prior to the first study.
- Known intolerance to or contraindication for glucocorticoid therapy.
- Prior exposure to a SINE compound.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Selinexor in combination with thalidomide and Dexamethasone
Selinexor in combination with thalidomide and Dexamethasone.
Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23.
Treatment will be administered in 28-day cycles,include a total of 12 cycles.
Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles.
Then Selinexor will be given at the recommended dose level on phase II.
|
100 mg/d, Po. på dag 1-28
Andre navn:
Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2).
Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
Andre navn:
20 mg/d Po. on day 1, 2,8,9,15,16,22,23
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Total responsrate (ORR)
Tidsramme: Vurdert fra datoen for første dose av studiebehandlingen til datoen som PD vurderte opp til 12 måneder
|
ORR i hver arm: delvis respons (PR) + veldig god delvis respons (VGPR) + fullstendig respons (CR)
|
Vurdert fra datoen for første dose av studiebehandlingen til datoen som PD vurderte opp til 12 måneder
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progresjonsfri overlevelse (PFS)
Tidsramme: 12 måneder
|
Varighet fra start av studiebehandling til PD eller død (uavhengig av årsak), avhengig av hva som kommer først
|
12 måneder
|
Clinical Benefit Rate (CBR)
Tidsramme: 12 måneder
|
Klinisk fordelsrate (CBR=ORR+Minor Response [MR])
|
12 måneder
|
Disease Control Rate (DCR)
Tidsramme: 12 måneder
|
Disease Control Rate (DCR=CBR+Stable Disease[SD; i minimum 12 uker])
|
12 måneder
|
Antall deltakere med uønskede hendelser
Tidsramme: Fra første dose med administrasjon av studiemedisin til behandlingsslutt (opptil 12 måneder)
|
Antall deltakere med behandlingsoppståtte bivirkninger (TEAEs) og behandlingsfremmede alvorlige bivirkninger (TESAEs)
|
Fra første dose med administrasjon av studiemedisin til behandlingsslutt (opptil 12 måneder)
|
Total overlevelse (OS)
Tidsramme: 12 måneder
|
Anslagene til Kaplan-Meier
|
12 måneder
|
Minimal Residual Disease (MRD)
Tidsramme: 12 måneder
|
For å evaluere den minimale gjenværende sykdommen hos CR- og sCR-pasienter
|
12 måneder
|
Varighet av respons (DOR)
Tidsramme: 12 måneder
|
Varighet fra første observasjon av minst PR til tidspunkt for sykdomsprogresjon, eller dødsfall på grunn av sykdomsprogresjon, avhengig av hva som inntreffer først.
|
12 måneder
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ting Niu, M.D., Ph.D, West China Hospital
- Hovedetterforsker: Li Zheng, M.D., Ph.D, West China Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hematologiske sykdommer
- Hemoragiske lidelser
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Multippelt myelom
- Neoplasmer, plasmacelle
- Fysiologiske effekter av legemidler
- Anti-infeksjonsmidler
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Antibakterielle midler
- Leprostatiske midler
- Deksametason
- Thalidomid
Andre studie-ID-numre
- ATG-010-IIT-MM-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multippelt myelom
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)AvsluttetMyelom, multippel | Myelom-multippelForente stater
-
Tel-Aviv Sourasky Medical CenterFullførtPlasmacellemyelom | Myelom-multippel | Myelom multippel | Myelom, plasmacelleIsrael
-
National Cancer Institute (NCI)Georgetown University; Hackensack Meridian HealthAvsluttetMyelom-multippel | Myelom, plasmacelle | MyelomatoseForente stater
-
University of ChicagoNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...FullførtStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Celgene CorporationAvsluttetStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TilbaketrukketStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom
Kliniske studier på Thalidomid
-
Norwegian University of Science and TechnologyThe Research Council of Norway; Nordic Myeloma Study Group, GermanyFullført
-
Changzhou No.2 People's HospitalUkjentKreft i spiserøretKina
-
Roswell Park Cancer InstituteFullførtUspesifisert solid barndomssvulst, protokollspesifikk | Uspesifisert voksen solid svulst, protokollspesifikk | Pode versus vertssykdomForente stater
-
Washington University School of MedicineCelgene CorporationFullført
-
Celgene CorporationFullførtMyelodysplastiske syndromerForente stater
-
Centre Hospitalier Universitaire, AmiensFullførtPrecancerøs tilstand | Non Neoplastic ConditionFrankrike
-
New York University Cancer InstituteNational Cancer Institute (NCI)Fullført
-
National Cancer Institute (NCI)FullførtHode- og nakkekreftForente stater
-
Beth Israel Deaconess Medical CenterFullførtLymfom | LeukemiForente stater
-
G.V. (Sonny) Montgomery VA Medical CenterUkjentHepatitt C virusinfeksjon | Infeksjon | Herpesvirus 2, HumanForente stater